Anticholinergic medication vs placebo
- Anticholinergic medication for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 0 participantsGRADE not reported
It is very uncertain whether CHOLINERGIC DRUGS changes acceptability of treatment: Leaving the study early compared with PLACEBO (very low certainty).
It is very uncertain whether DOPAMINERGIC DRUGS changes acceptability of treatment: Leaving the study early compared with PLACEBO (very low certainty).
It is very uncertain whether NORADRENERGIC DRUGS changes acceptability of treatment: Leaving the study early compared with PLACEBO (very low certainty).
It is very uncertain whether adjunctive carbamazepine + antipsychotics changes acceptability of treatment Leaving the study early due to any reason compared with placebo/no adjunctive treatment + antipsychotics (very low certainty).
It is very uncertain whether perazine changes acceptability of treatment Leaving the study early due to any reason compared with placebo (very low certainty).
Maintenance treatment with antipsychotic drugs leads to lower leaving the study early: due to any reason (acceptability of… compared with placebo/no treatment (high certainty).
It is very uncertain whether ANXIOLYTIC ‐ BUSPIRONE changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).
It is very uncertain whether FATTY ACID ‐ ETHYL‐EPA changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).
It is very uncertain whether HERB ‐ GINKGO BILOBA changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).
It is very uncertain whether POLYPEPTIDE ‐ CERULETIDE changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).
It is very uncertain whether ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).
It is very uncertain whether ANTIEPILEPTIC ‐ LEVETIRACETAM changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).
It is very uncertain whether VITAMIN E changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).
It is very uncertain whether ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS changes leaving the study early due to any reason (overall acceptability of… compared with PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS (very low certainty).
It is very uncertain whether BENZODIAZEPINES AS SOLE TREATMENT changes leaving the study early due to any reason (overall acceptability of… compared with PLACEBO (very low certainty).
It is very uncertain whether benzodiazepines changes acceptability of the treatment (measured by participants leaving the… compared with placebo (very low certainty).
It is very uncertain whether VALPROATE + ANTIPSYCHOTICS changes leaving the study early: Acceptability of treatment Leaving the… compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (very low certainty).